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LETTER TO THE EDITOR
Response to the letter from Dr Cosolo and Colleagues
Sir - We believe, like Dr Cosolo and colleagues, that studies
of the pharmacokinetics and metabolism of cytotoxic drugs
will yield important information on the relationship between
these variables and the clinical effects of response and tox-
icity. At present we are conducting pharmacokinetic and
metabolic studies on a number of cytotoxic drugs.
In the study we described, methotrexate pharmacokinetics
were investigated in 127 patients on up to three occasions.
We agree that ideally serum concentrations should have been
measured over 48 h, however, this requires patients to be in
hospital for 2 days for research purposes. We have previously
carried out such detailed investigations in thirty patients
(Pearson et al.,1985; Pearson, 1988) but it was not possible in
this large cohort of children to carry out such detailed
pharmacokinetic studies. Therefore we undertook a more
limited study in a larger number of patients in order that we
could relate pharmacokinetics to outcome.
However, we believe we applied appropriate pharma-
cokinetic principles in our study. We defined clearly that the
area under the serum concentration curve (AUC) which we
examined was that from zero to 24 h. From our previous
work (Pearson, 1988) the AUC from 24 to 48 h contributes
less than 8% of the total AUC from zero to 48 h, therefore
the effect of not studying serum concentrations after 24 h
should be very small.
In our opinion the concept of a median plasma methotrex-
ate concentration is appropriate, as methotrexate toxicity has
been correlated with time above a certain serum concentra-
tions rather than for total AUC.
Yours etc,
A.D.J. Pearson
Senior Lecturer in
Paediatric Oncology
Department of Child Health
The Medical School
University of Newcastle upon Tyne
Framlington Place
Newcastle upon Tyne
NE2 4HH
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